Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. Fifty patients who had relapsed (n=25) after or were resistant (n = 25) to chemotherapy were ...

Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer Agency PURPOSE: We conducted a retrospective ...

Combining Fludara (fludarabine), Cytoxan (cyclophosphamide), and Rituxan (rituximab) was safer and produced a higher response than pairing Campath (alemtuzumab) with Fludara and Cytoxan in patients ...

NEW YORK (Reuters) - Genzyme Corp held its second investor meeting in two months to argue that its most promising experimental drug will capture five times the sales that Sanofi-Aventis has assumed in ...

A study published this January by dermatologists at Brigham and Women’s Hospital may transform the way physicians approach treatment for leukemic cutaneous T-cell lymphoma (L-CTCL). L-CTCL is a cancer ...

A 43-year-old woman presented to our clinic with severe PUK and systemic features of WG. She had multiple negative C and P-ANCA. Clinically, she had a flattened nasal bridge and bilateral ...

Genzyme is stepping up its presence in the currently hot oncology world by extending relationships with Bayer Healthcare for three drugs compounds. The deal between the two biotech companies will ...

One of the big sticking points in the potential Sanofi-Aventis/Genzyme deal has been sales estimates for Campath, the company's leukemia drug that it's developing for multiple sclerosis. Genzyme has ...

When news broke in October that an approved cancer therapy had, for the first time, halted the progress of multiple sclerosis (MS), excitement was tangible among clinicians and patient groups. The ...

The US Food and Drug Administration has issued a safety warning about Genzyme and Schering AG’s Campath (alemtuzumab) in patients with multiple sclerosis, more than two months after a patient died ...